Endocrinology & Women s Health + Adult Immunizations Exotic Asia CME Cruise June 15 24, Menopause & Osteoporosis update 2015.
|
|
- Wendy Shelton
- 8 years ago
- Views:
Transcription
1 Menopause and Osteoporosis Update 2015 Post WHI-Update CCFP, MHSc, FRCP,FCFP,, NAMS Accredited Menopause Expert Associate Professor University of Toronto 1
2 Canadian Population Pyramid: The Silver Tsunami Age 55 In 2009 Source: Statistics Canada Catalogue no , Annual Demographic Statistics 2005, page 6 2
3 What s Not New in the Update Lifestyle counseling is essential to reduce risks of chronic conditions (CVD, cancer) HT remains the single most effective treatment for distressing VMS The primary indication for systemic HT is for relief of moderate to severe VMS Systemic HT may and topical HT will relieve symptoms of UGA HT will prevent or alleviate somatic pain associated with loss of estrogen 3
4 What s Not New in the Update HT will reduce the rate of osteoporotic fractures, colorectal cancer (EPT), and metabolic syndrome but is not solely recommended to prevent these conditions. HT is not recommended for prevention of CVD or dementia HT increases the risk for VTE, ischemic stroke, GB disease, and breast cancer Potential benefits and potential risks need to be placed into perspective in the discussion about use of HT for QOL issues 4
5 What is New in the Update Evidence suggests that most CAM therapies for VMS are little more than placebo Safety data on CAMs is lacking and in the face of accumulating evidence of drug interactions and toxicity these should not be recommended for VMS 5
6 What is New in the Update There is no convincing evidence for an increase in the risk of CAD in newly menopausal women starting hormone therapy..women should be reassured about this! The absolute risk of breast cancer with short term exposure is small and compares favourably to risk related to common lifestyle choices women omen can be reassured ed about this! To reduce the small risk of stroke in women taking HT risk factors should be addressed Use lowest effective dose but no absolute time limit 6
7 Other Messages to Reinforce Women with premature menopause should be advised to stay on HT until the natural age of menopause There is no evidence that this will increase their risk of breast cancer and it will decrease both bone loss and coronary artery calcium deposition HT may alleviate depression in the perimenopausal transition but not at later stages of menopause 7
8 The Women s Health Initiative The largest single study ever conducted by the NIH..cost over $625 million Primary endpoints of HT arms: Effects of HT on CHD (non fatal MI and death) with breast cancer as the primary adverse outcome 8
9 The Women s Health Initiative EPT arm stopped prematurely in May 2002 at 5.2 yrs instead of the planned 8 yrs due to unexpected adverse effects (MI, stroke, breast cancer) E alone arm stopped prematurely in Feb 2004 at 6.8 yrs due to increased stroke risk 9
10 The WHI: The Chosen Methodology Instead the investigators recruited women in their 50 s, 60 s and 70 s Largest, most expensive study ever conducted by the NIH in the USA RCTs in two groups (16,000 women with a uterus and 10, women after hysterectomy) assessed effects of HT on CVD and breast cancer 10
11 2002 WHI Results Appeared to Counter Prevailing Opinion First reports stated that that HT increased heart attack and stroke Subsequent reports emphasized increased risks of breast cancer, dementia Unable to assess the benefits for vasomotor symptoms because most of the older population were not having hot flushes to start with Confirmed the effectiveness of HT for reduction in osteoporotic fractures, DM, and colorectal cancer 11
12 What the WHI Told the World About HT ( ) 2006) DOES NOT improve QOL PROTECTS bone and prevents fractures Ca AND VIT D SUPPLEMENTS DO NOT PREVENT FRACTURES LOW FAT DIET DOES NOT REDUCE CVD INCREASES MI STROKE INCREASES breast cancer risk INCREASES cognitive impairment and dementia INCREASES urinary incontinence 12
13 Media Commentary in July 2002 Results of the WHI E&P Arm: Results were cited in the in the media as relative risks: 29% increased risk of CHD 41% increased risk of stroke 26% increased risk of breast cancer Women and their health care providers were alarmed Widespread discontinuation of HT 13
14 Estrogen Alone Media Reports from 2004 WHI Results were again cited in the in the media as relative risks: 39% increased risk in stroke The Data and Safety Monitoring Board concluded that the study should be stopped prematurely because the risks exceeded benefits without addressing the fact that most women in the study did not have hot flashes Reinforced the negative messages from the E&P arm 14
15 Different Ways to Express Breast Cancer for HT users in WHI Relative risk (RR) Ratio of risk between users and non users 1.24 means a 24% increase above baseline Absolute risk Baseline risk x the RR 30/ 10, x 1.24 = 38/10, Attributable risk 8 8 cancers per 10,000 women = 0.08% per year after 5 years of exposure 15
16 Putting Risks into Perspective The WHO Terminology for Adverse Event Rates Very common Common Uncommon Rare Very rare >1/10 1 to 10/100 1 to 10/1, /10, <1/10,000 Council for International Organizations of Medical Sciences (CIOMS). Guidelines for preparing core clinical-safety information on drugs. 2 nd edition. Geneva:CIOMS:
17 WHI E+P: Results Absolute Risks & Benefits No /Yr/10, CEE/MPA Placebo More Cases in E+P Group No Significant Difference in # of Cases Fewer Cases in E+P Group CHD* Stroke Breast Cancer VTE PE Endometrial Cancer Total Deaths Colorectal Cancer Hip Fractures Women's Health Initiative Steering Committee. JAMA 2004;291: Attrib Risk/10,000/yr 17
18 WHI E Arm: Absolute Risks & Benefits 90 No /Yr/10, More Cases in E Group CEE Placebo No Significant Difference in # of Cases Fewer Cases in E Group Strokes VTE CHD Breast Cancer PE Colorectal Cancer Total Deaths Hip Fractures Women's Health Initiative Steering Committee. JAMA 2004;291: Attrib Risk/10,000/yr 18
19 Why So Much Confusion? Average age was 63.6 years Data from an older menopausal population may not apply to younger, newly menopausal women Results were not widely presented as absolute or attributable risks Results were not put into perspective with other risks s that many women take 19
20 Menopause & Osteoporosis update 2015 Alarming g News Accounts 20
21 The Media has a Pervasive Impact on Public Perceptions of Risk Research has shown that strong beliefs about risk, once formed, change very slowly l and are extraordinarily persistent in the face of contrary evidence Vincent Convello, Centre for Risk Communication, Columbia University 21
22 Consequences of the Initial WHI Reports Both doctors and patients became fearful of HT Many doctors advised discontinuation of HT and 50% of users stopped. Fueled a multi-billion dollar market in alternative and complementary products for the relief of menopausal vasomotor symptoms As many as a 25% of those who stopped HT returned to their doctors for permission i to resume treatment 22
23 What is the Association between HT and MI? 23
24 Critical Examination of the WHI Results: Did the Advanced Age of Participants Influence Results? Characteristic Age at screening CEE/MPA n = 8506 Placebo n = years 2839 (33.4) 2683 (33.1) years 3853 (45.3) 3657 (45.1) years 1814 (21.3) 1762 (21.7) 24
25 Critique of WHI Interpretation of CHD Results: 2002 By analogy, if the WHI had sought to test whether vigorous exercise was useful for primary prevention of CHD, and had used the same study population, it is likely that an excess of heart attacks in the older age groups assigned to exercise might have led to the conclusion that exercise initiated at the time of menopause was not helpful from primary protection from CHD Reid RL. Editorial: Translating the Latest Scientific Advances into Clinical Practice. JOGC
26 Age Does Matter Women in their 50 s have half the (baseline) risk of women in their 60 s and one quarter the risk of women in their 70 s Hulley SB, Grady D. Editorial. JAMA 2004;291(14):
27 Secondary Analysis of WHI Data Rossouw J, et al JAMA 2007;297(13):
28 WHI HT Trials: Absolute Risk of CHD by Age Age group Cases / 100 person-yrs CHD Combined Trials* PBO ** CEE+MPA PBO ** Absolute Risk per 10,000 Person-Years **P<0.05 vs 50 to 59 yrs 28
29 HT Can Precipitate Coronary Events in Older Women Good evidence of a small increase in risk of MI from both HERS and WHI Any consideration of initiation of HT in older women should require appropriate counselling and careful assessment and management of CV risks 29
30 WHI HT Trials: Total Mortality by Age HR (95% CI) Unopposed CEE y 0.71 (0.46 to 1.11) y 1.02 (0.80 to 1.30) y 1.20 (0.93 to 1.55) CEE+MPA y 0.69 (0.44 to 1.07) y 1.09 (0.83 to 1.44) y 1.06 (0.80 to 1.41) Both arms* y 0.70 (0.51 to 0.96) y 1.05 (0.87 to 1.26) y 1.14 (0.94 to 1.37) Hazard Ratio for Mortality 30
31 Hormone Therapy Redeemed By Alice Park, April 5, 2007 If women start hormone therapy within the first 10 years after onset of menopause to treat hot flashes and night sweats, and remain on the hormones for no more than four to five years, they can take the fear of heart disease out of the question. Dr. Jacques Rossouw, lead author of WHI studies 31
32 WHI re-analysis: 7.4 yrs treatment and 1.3 yrs post trial CT Scans of Heart Coronary Artery Calcification in yo CEE Placebo Score OR < >300 (67.7%) 71 (18.3%) 29 (7.5%) (54.3%) 78 (22.2%) 45 (12.8%) (6.5%) (10.8%) 1.00 (referent) 0.67 ( ) 0.43 ( ) 0.80) ( ) 0.73) Manson JE et al. NEJM 2007;356:
33 Hormone Therapy After Oophorectomy Lowers CAC WHI secondary analysis in 2008 After hysterectomy: BSO and no HT: OR 2.0 for elevated CAC vs no BSO BSO and HT: OR 1.0 for elevated CAC vs no BSO Conclusion: HT within 5 years of BSO protective Allison MA et al. for the WHI. Menopause (4):
34 HT After Premature Loss of Ovarian Function Findings are consistent with the thesis that the estrogen deficiency associated with bilateral oophorectomy is related to an increased burden of calcified plaque in the coronary arteries that can be countered by HT Allison MA et al. for the WHI. Menopause (4):
35 Is HT Cardioprotective in Newly Menopausal Women? We will probably never get the answer To demonstrate at 10% reduction in cardiovascular mortality in normal women aged ,000 women would have to remain compliant with hormones or placebo for 10 years Depypere HT et al.. Climacteric 2007; 10:
36 What Happened After Reports from the WHI: Management of Hot Flushes? Put up with it advice ignored the fact that symptoms can be extremely disruptive, affect 65% of menopausal women 20% seek medical help may last for 5-7 years in 15% even longer! Reluctance to prescribe HT caused many women to turn to CAMs 36
37 CAMs: Where s the Evidence? Systematic review.. Although individual trials suggest benefits from certain therapies, data are insufficient to support the effectiveness of any complementary and alternative therapy in the management of menopausal symptoms. * *1) Nedrow et al. Arch Intern Med 2006; 166(14): ) Speroff L. Intern J Fertility & Womens Medicine 2005; 50(3): ) Kronenberg F,et al. Ann Intern Med 2002; 137: ) Huntley ALet al..menopasue 2003; 10(5): ) NAMS. Menopause 2003: 11(1):
38 Menopausal Hot Flushes Remain the Primary Indication for HT If hot flushes are mild and not distressing lifestyle changes may reduce the frequency and severity of symptoms For moderate to severe vasomotor symptoms: Complementary medicines not recommended No treatment is as effective as HT If HT unacceptable try SNRIs Other non hormonal therapies may be tried (gabapentin, clonidine, bellergal etc) 38
39 Urogenital Ageing Bladder Urgency Frequency Recurrent UTI Vagina Dryness Painful intercourse Recurrent infection 39
40 Risks of HT Keeping perspective p 40
41 HT and Cardiovascular Disease in Women The definitive study on CVD benefits/ risks is lacking.. no RCT has recruited sufficient i numbers of newly menopausal women and followed them long term HT does not increase risk of CAD in newly menopausal women when started on HT within the first 10 years after menopause Women with premature menopause may be less likely to develop CVD if maintained on HT until the usual age of menopause Healthy life choices and the use of established medications for CVD prevention should remain the mainstay of strategies to reduce CVD in our aging population 41
42 HT and Risk of Stroke WHI reported an increased risk of stroke : 73% of women in WHI were in Framingham medium high risk for stroke (obese, smokers, hypertensive) The absolute risk for the entire population was 0.8/1000 (CEE) and 1.2/1000 woman-years (CEE/MPA) Other research found no increased risk of stroke Lobo (2004) stroke risk was decreased eased in 6681 newly menopausal women started on HT Wisdom Trial in UK (2007): no increased stroke in 2196 women on HT compared to placebo Always important to address stroke risk factors: Obesity, hypertension, smoking, etc 42
43 Dementia and HT: Re-Analysis of the WHIMS study Prior hormone users experienced significantly lower risks of Alzheimer s disease and all-cause dementia during WHIMS trials. Whereas hormone therapy initiated after age 65 increases dementia risk, these new findings support the need for further research on cognitive consequences of hormone initiation at earlier ages. Henderson VW, Espeland MA, Hogan PE, Rapp SR, Stefanick ML,et al. Prior Use of Hormone Therapy and Incident Alzheimer,s Disease in the Women s Health Initiative Memory Study Neurology 68 [suppl.1]:a205,
44 HT and Risk of VTE Menopausal HT very slightly increases the risk of a blood clot (2-3 additional cases per 10, users) The risk is greatest in the first year of use Age is greater risk factor: risk doubles risk quadruples Weight Overweight 1.96 ( ) Obese 3.09 ( ) Risk is reduced with lower doses and transdermal HT 44
45 Hormone Therapy and Breast Cancer Lifetime exposure to hormones linked to hormone receptor positive breast cancer Early menarche, late menopause Late first pregnancy Breast feeding Numerous studies indicate a small increase in risk of breast cancer with longer term HT (more so for combined EPT than ET alone) 45
46 WHI CEE/MPA : Overall HR and Attributable Risks/ Benefits Health Event CHD Stroke Breast cancer VTE Colorectal cancer Hip fractures Overall Hazard Ratio Confidence Interval Nominal 95% Adjusted 95% Attributable Risk per 10,000 Women/Year Attributable Benefit per 10,000 Women/Year Total fractures Writing Group for the Women's Health Initiative Investigators. JAMA. 2002;288:
47 WHI: Breast Cancer Results EPT Arm: Women with no prior hormone exposure: HR 1.09 (CI ) <5yrs prior use HR 1.70 (CI ) >5 yrs prior use HR (CI ) E Arm: No increased risk during 7 years HR 0.77 (CI ) 74% 74% had no prior HT exposure Chlebowski RT et al. JAMA 2000; (24):
48 Breast Cancer: Risks of developing or dying per decade Age Cases of Br Ca /1,000 Br Ca Deaths /1,000 All cause Deaths /1, Fletcher SW, Elmore JG. NEJM 2003; 348(17):
49 Editorial 2006 Collins JA Obstet Gynecol 2006;108(6):
50 Breast Cancer: Keeping Perspective When menopausal women present with distressing vasomotor symptoms, they can be reassured that short term (less than 5 years) use of either combined EPT or E alone will have little appreciable effect on their personal breast cancer risk. Longer use of combined EPT undeniably increases their breast cancer risk likely to a greater extent than exposure to E alone. However, the level of risk remains similar to risks that many women accept through lifestyles that expose them to daily alcohol ingestion, lack of regular exercise and postmenopausal obesity. Collins JA Obstet Gynecol 2006;108(6):
51 HT Risks Exaggerated by the Media A recent comprehensive analysis of breast cancer news in leading media outlets found that articles on breast cancer risk factors tended to focus on HT while ignoring equally important modifiable risk factors that could have a major impact on breast cancer rates in developing countries. Atkin CK et al. A Comprehensive Analysis of Breast Cancer News Coverage in Leading Media Outlets Focusing on Environmental Risks and Prevention J Health Communication 2008; 13:
52 Lifestyle contributions to Breast Cancer Risk Analysis of modifiable risk factors that could be altered after menopause has been attained suggest that a substantial fraction of postmenopausal breast cancers (34%) may be avoided by purposeful changes in lifestyle lf l later in life (Sprague 2008) Sprague BL et al. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol2008; 168(4):
53 Comparison of HT and other Factors as Risks for Breast Cancer EPT > 5 yrs use 1.3 Early menarche 1.3 Late menopause Late ae first peg pregnancy Chest radiation Postmenopausal obesity 1.2 Alcohol use Age > First degree relative Br Ca > First degree relative Br Ca < BRAC gene mutation 200 Singletary SE. Ann Surg 2003; 237:
54 Risk Factors for Breast Cancer affected relatives Obesity Risk Relative Young menarche HRT>5 years 1 st child >age 30 1 year post HRT 5 years post HRT Alcohol Exercise Menopause < years oophx
55 Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy LaCroix et al JAMA April Health Event CHD MI Deaths MI Attributable Risk per 10,000 Women/Year Overall reduction in Breast Cancer was 27% over the placebo group Deaths Attributable Benefit per 10,000 Women/Year Writing Group for the Women's Health Initiative Investigators. JAMA. 2002;288:
56 Hormone Therapy: What can we say with reasonable confidence in 2015? Nothing is as effective as HT for vasomotor symptoms and most CAM act as placebos HT will relieve joint pain and prevent bone loss when used for vasomotor symptoms Systemic HT may, and intra-vaginal estrogen will, relieve urogenital atrophy HT used at menopause does not increase risk of CAD and used for 5 years or less has little appreciable effect on breast cancer risk 56
The Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention
The Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention Robert B. Wallace, MD, MSc Departments of Epidemiology and Internal Medicine University of Iowa College of Public Health
More informationHormone therapy and breast cancer: conflicting evidence. Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group
Hormone therapy and breast cancer: conflicting evidence Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group The world of hormone therapy in the 1990 s Throughout the 1970s, 1980s and 1990s
More informationThe menopausal transition usually has three parts:
The menopausal transition usually has three parts: Perimenopause begins several years before a woman s last menstrual period, when the ovaries gradually produce less estrogen. In the last 1-2 years of
More informationThe Women s Health Initiative where are we a decade later?
The Women s Health Initiative where are we a decade later? Henry G. Burger MIMR-PHI Institute & Jean Hailes for Women s Health, Melbourne, Australia Disclosures: Henry Burger Sources of Funding Pharmaceutical
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationHormone replacement therapy:
www.bpac.org.nz keyword: hrt Hormone replacement therapy: latest evidence and treatment recommendations Key advisor: Dr Helen Roberts, Senior Lecturer, Department of Obstetrics and Gynaecology, Faculty
More information(212) 733-2324 mackay.jimeson@pfizer.com
For immediate release: July 9, 2012 Media Contacts: MacKay Jimeson (212) 733-2324 mackay.jimeson@pfizer.com Pfizer Recognizes 10 th Anniversary Of The Women s Health Initiative: A Modern Day Perspective
More informationMenopause Guidance on management and prescribing HRT for GPs based on NICE guidance 2015
PRIMARY CARE WOMEN S HEALTH FORUM GUIDELINES Menopause Guidance on management and prescribing HRT for GPs based on NICE guidance 2015 Written by Dr Imogen Shaw This guidance is designed to support you
More informationRandomized trials versus observational studies
Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationWOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500. Hormone Therapy
Hormone Therapy WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 At menopause, a woman's body makes less estrogen and she stops having menstrual periods. This is a natural stage in a woman's
More informationpatient education Fact Sheet PFS003: Hormone Therapy APRIL 2015
patient education Fact Sheet PFS003: Hormone Therapy APRIL 2015 Hormone Therapy Menopause is the time in a woman s life when she naturally stops having menstrual periods. Menopause marks the end of the
More informationHormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.
Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms
More informationHormone. Replacement. Therapy. Information leaflet. This information is also available on request in other formats by phoning 01387 241053.
Hormone Replacement Therapy This information is also available on request in other formats by phoning 01387 241053. Information leaflet Produced by Dr H Currie & Sr. K Martin May 2005 Updated Dec. 2013
More informationChickenpox and Shingles Vaccines
Chickenpox and Shingles Vaccines The chicken pox/shingles connection DISCLAIMER: The following is not intended as advice on whether or not to receive a chicken pox, shingles, or any other vaccine. The
More informationHormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions
Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions IMPORTANCE OF HORMONE BALANCE Importance of Hormone Balance Help you live a long, healthy life Help you
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationNeal Rouzier responds to the JAMA article on Men and Testosterone
Neal Rouzier responds to the JAMA article on Men and Testosterone On the first day the JAMA article was released I received 500 emails from physicians and patients requesting my opinion of the article
More informationHow To Know The Benefits And Risks Of Hormone Therapy
Menopause: The Journal of The North American Menopause Society Vol. 19, No. 3, pp. 257/271 DOI: 10.1097/gme.0b013e31824b970a * 2012 by The North American Menopause Society POSITION STATEMENT The 2012 Hormone
More informationWhat is the Menopause?
What is the Menopause? This information is also available on request in other formats by phoning 01387 241053. Information leaflet Produced by Dr H Currie & Sr. K Martin May 2005 Checked 2013 Review 2015
More informationObesity and the Menopause. Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology
Obesity and the Menopause Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology Educational Objectives Review normal menopausal transition Review health risks of obesity
More informationMenopause: should I take HRT?
Patient information from the BMJ Group Menopause: should I take HRT? The menopause is when your periods stop for good. It isn't an illness. It's a normal part of every woman's life. But sometimes it causes
More informationECONOMIC COSTS OF PHYSICAL INACTIVITY
ECONOMIC COSTS OF PHYSICAL INACTIVITY This fact sheet highlights the prevalence and health-consequences of physical inactivity and summarises some of the key facts and figures on the economic costs of
More informationIf you are still in your fertility years If you are past your fertility years and need surgery for a mass or for pain and have normal ovaries
If you are still in your fertility years, an ovary should be removed only if there is a large, complex or persistent mass on it or if you have intolerable pain from endometriosis. There should be an attempt
More informationStress is linked to exaggerated cardiovascular reactivity. 1) Stress 2) Hostility 3) Social Support. Evidence of association between these
Psychosocial Factors & CHD Health Psychology Psychosocial Factors 1) Stress 2) Hostility 3) Social Support Evidence of association between these psychosocial factors and CHD Physiological Mechanisms Stress
More informationMenopause & Hormone Therapy
Menopause & Hormone Therapy The Verdict! In 2012 there were two important medical articles that brought clarity to a decade of fear and confusion regarding the risks and benefits of hormone therapy in
More informationThe Menopause and Subtotal Hysterectomy
Oxford University Hospitals NHS Trust Women s Health The Menopause and Subtotal Hysterectomy Information for patients The menopause At the menopause the ovaries stop working. This means that the female
More informationHealth risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study
DOI 10.1007/s00198-012-2224-2 ORIGINAL ARTICLE Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study R. L. Prentice & M. B. Pettinger
More informationPROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES. Richard L. Tannen, M.D., Mark Weiner, Dawei Xie
PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES Richard L. Tannen, M.D., Mark Weiner, Dawei Xie GOALS OF STUDY Determine Whether Studies Using EMR Database Yield Valid Outcome Assessment Major
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More informationNow that your Doctor has prescribed Livial for you
Now that your Doctor has prescribed Livial for you This educational brochure is only for use by patients prescribed LIVIAL The Menopause The term menopause refers to the very last menstrual period a woman
More informationCOULD IT BE LOW TESTOSTERONE?
COULD IT BE LOW TESTOSTERONE? By Dr. Lauren M. Bramley For thousands of years women have been recognized for their sensitivity to hormones. PMS, post partum depression, menopause have long been plights
More informationI will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too?
What is node-positive breast cancer? Node-positive breast cancer means that cancer cells from the tumour in the breast have been found in the lymph nodes (sometimes called glands ) in the armpit area.
More informationShira Miller, M.D. Los Angeles, CA 310-734-8864 www.shiramillermd.com. The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library
Shira Miller, M.D. Los Angeles, CA 310-734-8864 The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library 2 Outline What is hormone therapy? Why would healthy men and women need to think about
More informationBio-Identical Hormone FAQ s
Bio-Identical Hormone FAQ s What are bio-identical hormones? They are derived from a natural plant source and professionally compounded to be biologically identical to human form of estradiol and testosterone.
More informationTestosterone Treatment in Older Men
Testosterone Treatment in Older Men J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships to disclose.
More informationSmoking and Age of Menopause. Women who smoke experience menopause an average of 2 years earlier than women who do not smoke.
Menopause Menopause Feared event To many, it indicates old age - a sign of life coming to a close. Many expect a difficult psychological adjustment to menopause (bad press, bad jokes). Menopause Effect
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This is an updated guideline It incorporates the latest NICE guidance There are strong recommendations for calcium + vitamin D
More informationButler Memorial Hospital Community Health Needs Assessment 2013
Butler Memorial Hospital Community Health Needs Assessment 2013 Butler County best represents the community that Butler Memorial Hospital serves. Butler Memorial Hospital (BMH) has conducted community
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationSumma Health System. A Woman s Guide to Hysterectomy
Summa Health System A Woman s Guide to Hysterectomy Hysterectomy A hysterectomy is a surgical procedure to remove a woman s uterus (womb). The uterus is the organ which shelters and nourishes a baby during
More informationWhat is the menopause and what are the symptoms?
What is the menopause and what are the symptoms? Strictly speaking, the menopause is the last menstrual period. However, most women think of the menopause as the time of life leading up to, and after,
More informationIf you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationHormones and cardiovascular disease, what the Danish Nurse Cohort learned us
Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us Ellen Løkkegaard, Clinical Associate Professor, Ph.d. Dept. Obstetrics and Gynecology. Hillerød Hospital, University of Copenhagen
More informationBREAST CANCER RISK ASSESSMENT AND PRIMARY PREVENTION FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1
FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1 Hello, my name is Rachel Jankowitz, I m an assistant professor of medicine in the Division of Hematology Oncology at the University of Pittsburgh
More informationNIHI Big Data in Healthcare Research Case Study
NIHI Big Data in Healthcare Research Case Study Professor Rob Doughty Heart Foundation Chair of Heart Health National Institute for Health Innovation and the Dept of Medicine, University of Auckland &
More informationCoronary Heart Disease (CHD) Brief
Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs
More informationFebruary 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS
February 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS Calvin Hirsch, MD Professor of Clinical Internal Medicine (Geriatrics) UC Davis School of
More informationTestosterone for women, who when and how much?
Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,
More informationPromoting the Fountain of Youth: Low-T and Estrogen Deficiency
Promoting the Fountain of Youth: Low-T and Estrogen Deficiency Adriane Fugh-Berman MD Georgetown University Medical Center ajf29@georgetown.edu Hormone Therapy in Women Animal glandulars became popular
More informationAspen Chiropractic & Wellness
WELCOME TO OUR OFFICE We are committed to providing you the best of care and are pleased to discuss our professional fees with you at any time. Please ask any questions you may have regarding our fees
More informationCase Study 11: Hormone Replacement Therapy
Case Study 11: Hormone Replacement Therapy October 2000 Scenario Ann McDonnald is a successful 55 year old business executive She starts her first consult with you by saying I m getting hot flushes It
More informationPerformance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis
Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis Methodology: 8 respondents The measures are incorporated into one of four sections: Highly
More informationDepression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
More informationLakeview Endocrinology and Diabetes Consultants. 2719 N Halsted St C-1. Chicago IL 60614 P: 773 388 5685 F: 773 388 5687. www.lakeviewendocrinolgy.
Lakeview Endocrinology and Diabetes Consultants 2719 N Halsted St C-1 Chicago IL 60614 P: 773 388 5685 F: 773 388 5687 www.lakeviewendocrinolgy.com Patient information: Early menopause (premature ovarian
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 13 October 2005 Doc. Ref. EMEA/CHMP/021/97 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationNew and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents
New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine
More informationManaging Menopausal Symptoms Kirsten J. Lund, M.D. Associate Professor, OB-GYN University of Colorado
Managing Menopausal Symptoms Kirsten J. Lund, M.D. Associate Professor, OB-GYN University of Colorado Disclosures No ties, financial or otherwise, to pharmaceutical companies Will identify non-fda approved
More informationon a daily basis. On the whole, however, those with heart disease are more limited in their activities, including work.
Heart Disease A disabling yet preventable condition Number 3 January 2 NATIONAL ACADEMY ON AN AGING SOCIETY Almost 18 million people 7 percent of all Americans have heart disease. More than half of the
More informationBRCA Genes and Inherited Breast and Ovarian Cancer. Patient information leaflet
BRCA Genes and Inherited Breast and Ovarian Cancer Patient information leaflet This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could
More informationHow To Know The Risks And Benefits Of Estrogen Plus Progestin
ORIGINAL CONTRIBUTION JAMA-EXPRESS Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women s Health Initiative Randomized Controlled Trial Writing
More informationClient Information for Informed Consent TESTOSTERONE FOR TRANSGENDER PATIENTS
Client Information for Informed Consent TESTOSTERONE FOR TRANSGENDER PATIENTS You want to take testosterone to masculinize your body. Before taking it, there are several things you need to know about.
More informationNeuroendocrine Evaluation
Neuroendocrine Evaluation When women have health concerns they usually prefer to discuss them with another woman. Dr. Vliet is a national expert on hormone-related problems and specializes in neuroendocrine
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationEfficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women
Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women Irina Shestakova, MD, PhD Research Center of Obstetrics, Gynecology and Perinatology Department of
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More information11 Serious and life-threatening side effects can occur while taking EVISTA. These include 12 blood clots and dying from stroke:
1 1 BNL 3123 AMP 2 Medication Guide 3 EVISTA (E-VISS-tah) 4 (raloxifene hydrochloride) 5 Tablets for Oral Use 6 Read the Medication Guide that comes with EVISTA before you start taking it and each time
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationHRT. An overview of the risks of hormone replacement therapy. Lloyd s emerging risks team report
HRT An overview of the risks of hormone replacement therapy Lloyd s emerging risks team report 1 Disclaimer This document is intended for general information purposes only. Whilst all care has been taken
More informationBig data size isn t enough! Irene Petersen, PhD Primary Care & Population Health
Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health Introduction Reader (Statistics and Epidemiology) Research team epidemiologists/statisticians/phd students Primary care
More informationUnderstanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationUse of Hormone Replacement Therapy in the Asymptomatic Postmenopausal Woman: What is the Current Evidence?
CPD Paper 5 605 Use of Hormone Replacement Therapy in the Asymptomatic Postmenopausal Woman: What is the Current Evidence? F H Loh,*FAMS, MRCOG (Lond), M Med (O & G) Abstract The publication of the Women
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationBREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
More informationTestosterone Therapy for Women
Testosterone Therapy for Women The Facts You Need Contents 2 INTRODUCTION: The Facts You Need... 3-4 CHAPTER 1: Testosterone and Women... 5-9 CHAPTER 2: Testosterone Therapy for Women... 10-14 CONCLUSION:
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More information16. ARTHRITIS, OSTEOPOROSIS, AND CHRONIC BACK CONDITIONS
16. ARTHRITIS, OSTEOPOROSIS, AND CHRONIC BACK CONDITIONS Goal Reduce the impact of several major musculoskeletal conditions by reducing the occurrence, impairment, functional limitations, and limitation
More informationWith Big Data Comes Big Responsibility
With Big Data Comes Big Responsibility Using health care data to emulate randomized trials when randomized trials are not available Miguel A. Hernán Departments of Epidemiology and Biostatistics Harvard
More informationBreast Cancer in the Family
Oxford University Hospitals NHS Trust Oxford Regional Genetic Department Breast Cancer in the Family Information for women with a moderately increased risk of breast cancer Breast cancer in the family
More informationUsing Family History to Improve Your Health Web Quest Abstract
Web Quest Abstract Students explore the Using Family History to Improve Your Health module on the Genetic Science Learning Center website to complete a web quest. Learning Objectives Chronic diseases such
More informationABSTRACT. Home Current Issue All Issues Online First Specialties & Topics CME Multimedia Quizzes For Authors Subscribe
SIGN IN (Create a Free Personal Account) Journals > Specialties & Topics Store Physician Jobs About Mobile Search The JAMA Network Search JAMA Advanced Search Home Current Issue All Issues Online First
More informationMedications to Prevent and Treat Osteoporosis
Medications to Prevent and Treat Osteoporosis National Institutes of Health Osteoporosis and Related Bone Diseases ~ National Resource Center 2 AMS Circle Bethesda, MD 20892-3676 Tel: (800) 624-BONE or
More informationDr. Friedman s Guide to Estrogen Replacement
Dr. Friedman s Guide to Estrogen Replacement There are risks and benefits with all medicines and estrogen replacement is no exception. In fact, estrogen replacement is one of the most controversial topics
More informationAbigail R. Proffer, M.D. October 4, 2013
Abigail R. Proffer, M.D. October 4, 2013 Topics Human Papillomavirus (HPV) Vaccines Pap smears Colposcopy Contraception Polycystic Ovary Syndrome (PCOS) Can I get pregnant? Miscarriage Abnormal Uterine
More informationEMR Tutorial Acute Coronary Syndrome
EMR Tutorial Acute Coronary Syndrome How to find the Acute Coronary Syndrome AAA Home Page 1 of 26 Master Tool Bar Icon When the Template button is clicked you will be presented with the preference list.
More informationPresenting Genital Symptoms and Physical Signs of Vaginal Atrophy
Sexual Health in the Menopause Presenting Genital Symptoms and Physical Signs of Vaginal Atrophy Symptoms Dryness Itching Burning Dyspareunia Signs on Physical Exam Pale, smooth, or shiny vaginal epithelium
More informationWhat is a Heart Attack? 1,2,3
S What is a Heart Attack? 1,2,3 Heart attacks, otherwise known as myocardial infarctions, are caused when the blood supply to a section of the heart is suddenly disrupted. Without the oxygen supplied by
More informationHEALTH CARE COSTS 11
2 Health Care Costs Chronic health problems account for a substantial part of health care costs. Annually, three diseases, cardiovascular disease (including stroke), cancer, and diabetes, make up about
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationHow to get the most from your UnitedHealthcare health care plan.
How to get the most from your UnitedHealthcare health care plan. Your UnitedHealthcare health care plan includes many features and benefits that help you get the care you need and enjoy better overall
More informationHelping you manage symptoms and side effects associated with metastatic breast cancer treatment
Helping you manage symptoms and side effects associated with metastatic breast cancer treatment 2015 AstraZeneca. All rights reserved. 3156710 Last Updated 9/15 with metastatic breast cancer treatment
More informationForm ### Transgender Hormone Therapy - Estrogen Informed Consent SAMPLE
What are the different medications that can help to feminize me? Estrogen - Different types of the hormone estrogen can help you appear more feminine. Estrogen is the female sex hormone. Androgen blocker
More informationI. Background. II. Eligibility Geographic Scope: United States Only International(specify country/countries) Applicant Eligibility Criteria:
Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Enabling effective conversations regarding menopausal vasomotor symptoms and other conditions associated with menopause utilizing
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationX-Plain Chemotherapy for Breast Cancer - Adriamycin, Cytoxan, and Tamoxifen Reference Summary
X-Plain Chemotherapy for Breast Cancer - Adriamycin, Cytoxan, and Tamoxifen Reference Summary Introduction Breast cancer is a common condition that affects one out of every 11 women. Your doctor has recommended
More information